Search

GlaxoSmithKline PLC

Gesloten

SectorGezondheidszorg

1,389.5 -0.22

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1378.5

Max

1397

Belangrijke statistieken

By Trading Economics

Inkomsten

559M

501M

Verkoop

105M

8.1B

K/W

Sectorgemiddelde

21.557

57.333

EPS

23.2

Dividendrendement

4.79

Winstmarge

6.172

Werknemers

68,629

EBITDA

-52M

1.1B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+13.6% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.79%

2.63%

Volgende Winsten

30 apr 2025

Volgende dividenddatum

10 jul 2025

Volgende Ex Dividend datum

15 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-5.9B

54B

Vorige openingsprijs

1389.72

Vorige sluitingsprijs

1389.5

GlaxoSmithKline PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 apr 2025, 09:39 UTC

Belangrijke Marktbewegers

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

5 feb 2025, 11:32 UTC

Winsten

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook -- 2nd Update

5 feb 2025, 08:56 UTC

Winsten

Correction to GSK Article

5 feb 2025, 08:24 UTC

Winsten

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views -- Update

5 feb 2025, 07:43 UTC

Winsten

GSK Expects Further Profit Growth After Beating Market Views

23 apr 2025, 21:48 UTC

Top Nieuws

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

23 apr 2025, 20:47 UTC

Top Nieuws

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

23 apr 2025, 20:40 UTC

Top Nieuws

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

15 apr 2025, 09:55 UTC

Marktinformatie

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9 apr 2025, 07:23 UTC

Marktinformatie

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3 apr 2025, 08:41 UTC

Marktinformatie

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 apr 2025, 08:36 UTC

Marktinformatie

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3 apr 2025, 07:51 UTC

Marktinformatie

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2 apr 2025, 09:27 UTC

Populaire aandelen

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 mrt 2025, 22:29 UTC

Top Nieuws

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26 mrt 2025, 19:19 UTC

Top Nieuws

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26 mrt 2025, 17:39 UTC

Top Nieuws

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

19 mrt 2025, 14:50 UTC

Top Nieuws

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

17 mrt 2025, 09:00 UTC

Top Nieuws

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

24 feb 2025, 07:05 UTC

Acquisities, Fusies, Overnames

GSK Completes Acquisition of IDRx

14 feb 2025, 11:38 UTC

Top Nieuws
Winsten

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

14 feb 2025, 11:30 UTC

Top Nieuws
Winsten

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

5 feb 2025, 15:33 UTC

Marktinformatie
Winsten

GSK's Pipeline Has to Prove It Can Counter Concerns Over Vaccine Business -- Market Talk

5 feb 2025, 08:38 UTC

Marktinformatie
Winsten

GSK Needs to Show It Can Navigate Vaccines Challenge -- Market Talk

5 feb 2025, 07:05 UTC

Winsten

GSK PLC Had Seen 2031 Sales Outlook at More Than GBP38B

5 feb 2025, 07:04 UTC

Winsten

GSK PLC Sees 2031 Sales Outlook at More Than GBP40B

5 feb 2025, 07:03 UTC

Winsten

GSK PLC Sees 2025 Adjusted EPS Growth of 6%-8%

5 feb 2025, 07:03 UTC

Winsten

GSK PLC Raises Mid-Term View

5 feb 2025, 07:03 UTC

Winsten

GSK PLC Sees 2025 Adjusted Operating Growth of 6% - 8%

5 feb 2025, 07:02 UTC

Winsten

GSK PLC Sees 2025 Turnover Growth of 3% to 5%

GlaxoSmithKline PLC Prognose

Koersdoel

By TipRanks

13.6% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,583.64 GBX  13.6%

Hoogste 2,290 GBX

Laagste 1,350 GBX

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor GlaxoSmithKline PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

11 ratings

1

Buy

8

Hold

2

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.